Krystal Biotech, Inc. $KRYS Shares Purchased by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Krystal Biotech by 8,390.1% after purchasing 37,336 shares, raising its total ownership to 37,781 shares valued at approximately $6.81 million.
• Several institutional investors have also increased their holdings in Krystal Biotech, contributing to a total institutional ownership of 86.29% of the company's stock.
• Krystal Biotech recently reported earnings of $1.29 per share, exceeding expectations, with a net margin of 40.85% and projected full-year earnings of $6.14 per share.

Russell Investments Group Ltd. lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8,390.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,781 shares of the company's stock after acquiring an additional 37,336 shares during the period. Russell Investments Group Ltd. owned 0.13% of Krystal Biotech worth $6,812,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Fifth Third Bancorp boosted its stake in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Krystal Biotech during the fourth quarter worth $95,000. GAMMA Investing LLC boosted its stake in Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Krystal Biotech during the first quarter worth $223,000. Finally, Avanza Fonder AB boosted its stake in Krystal Biotech by 66.0% during the first quarter. Avanza Fonder AB now owns 1,260 shares of the company's stock worth $228,000 after buying an additional 501 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $4.79 during trading hours on Friday, hitting $150.49. The company's stock had a trading volume of 246,954 shares, compared to its average volume of 428,473. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84. The firm has a fifty day moving average of $144.22 and a 200-day moving average of $154.55. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of 30.59 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday. Bank of America lowered their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Chardan Capital lowered their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of "Buy" and a consensus price target of $210.38.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).